Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.

A duo of neurologists at Northwestern Medicine discussed the unmet needs in cluster headache and the diagnostic overlap with migraine that can delay care for patients. [WATCH TIME: 5 minutes]

The FDA has granted Scholar Rock's apitegromab fast track designation for the treatment of patients with living facioscapulohumeral muscular dystrophy as the company's phase 2 FORGE study dosing begins.

Tonic motor activation therapy was associated with reductions in RLS severity, along with tolerable reductions in dopamine agonist dosing, in adults with medication-refractory RLS.

The professor of neurology at the University of Cincinnati discussed why disparities persist in secondary stroke prevention and how growing awareness of social determinants of health is helping to close the gap for underserved patients.

Ulefnersen met its primary end point in the phase 3 FUSION trial, providing the first placebo-controlled evidence for a genetically targeted therapy in FUS-ALS.

A recently published study showed that Qihuang needle acupuncture significantly improved motor function, nonmotor symptoms, and quality of life in patients with PD when added to standard medication.

Here's some of what is coming soon to NeurologyLive® this week.

The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Fokas, MD, and Minali Nigam, MD. [LISTEN TIME: 21 minutes]

In honor of Muscular Dystrophy Awareness Month, held annually in September, NeurologyLive® looks back at the decade-long expansion of the DMD treatment landscape and the data that supports each approval.

The FDA clearance allows AbelZeta to study bispecific CAR T-cell therapy C-CAR168 in refractory progressive multiple sclerosis.

Results recently published from the phase 2 HIMALAYA trial reported that SAR443820 did not slow functional decline, and was associated with more adverse events and treatment discontinuations in patients with ALS.

A new study reported that tremor and myoclonus affected nearly 7 in 10 patients with chronic inflammatory demyelinating polyneuropathy, with immunotherapy and beta-blockers showing potential benefit for symptom improvement.

Michela Leocadi, PhD, research fellow at UCL Queen Square Institute of Neurology, discussed new longitudinal data showing early functional connectivity changes in HD gene carriers years before clinical motor diagnosis.

In a phase 4 randomized controlled trial, opicapone failed to demonstrate statistical superiority over placebo for reducing fluctuation-related pain in patients living with Parkinson disease.

KuangHua Guo, MD, PhD, sleep specialist at Northwestern Medicine, discussed emerging orexin agonist therapies and refined diagnostic approaches for hypersomnia.

Microstructure Imaging has announced that the FDA cleared its MICSI-PET, an MR-guided PET enhancement platform with automated amyloid Centiloid and tau quantification.

Newly published data of oveporexton from the phase 3 FirstLight and RadiantLight trials showed that the ageny improved wakefulness, sleepiness, cataplexy, and quality of life among patients with narcolepsy type 1.

A review of 12 studies showed that maternal migraine was linked to a higher likelihood of infant colic, and that infant colic was in turn linked to a higher risk of migraine later in childhood.

Here's some of what is coming soon to NeurologyLive® this week.

A new case report underscored the need to consider CNS lymphoproliferative disease when patients on chronic immunosuppression for neuromyelitis optica spectrum disorder develop unexplained neurologic decline.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 11, 2026.

The phase 3 LUNA study showed that atogepant, an oral calcitonin gene-related peptide receptor antagonist, significantly reduced perimenstrual migraine days among patients with menstrual migraine compared with placebo.

A newly launched global phase 3 trial will compare once-daily trientine to D-penicillamine as a first-line treatment for patients with Wilson disease, a rare genetic disorder.

New real-world data showed that daily corticosteroid therapy preserved motor function longer in patients with Duchenne muscular dystrophy compared with an intermittent dosing regimen.

The clinical neuropsychologist and assistant professor of medicine at the Icahn School of Medicine at Mount Sinai discussed the mechanisms behind brain fog from Long COVID and its potential links to Alzheimer risk.

A new study suggests excessive daytime sleepiness in obstructive sleep apnea may be associated with cognitive impairment and altered brain network connectivity in the middle frontal gyrus and inferior parietal lobule.

A recent study of Brazilian adolescents showed a high prevalence of excessive daytime sleepiness, with severe depressive symptoms and smartphone addiction emerging as the strongest independent risk factors.